Surface Oncology, Inc.
SURF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SURF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2023.
Tracking 5 pipeline candidates for Surface Oncology, Inc..
Run Surface Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Surface Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
8.5 months
D/E 0.34
Lead: Phase 1
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is Surface Oncology, Inc.'s lead drug candidate?
Surface Oncology, Inc.'s most advanced tracked candidate is gsk4381562 (Phase 1) for Cancer.
Who is the CEO of Surface Oncology, Inc.?
Robert W. Ross, M.D. is the chief executive officer of Surface Oncology, Inc. (SURF).
What therapeutic areas does Surface Oncology, Inc. focus on?
Surface Oncology, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.